Floatz logo

Sctb41

Double Blind

Sinocelltech Ltd.Phase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Double Blind cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Sinocelltech Ltd.
Phase 2/3B
Carboplatin
Sinocelltech Ltd.
Phase 2/3B
Tislelizumab
Sinocelltech Ltd.
Phase 2/3B
rc48-adc
Sinocelltech Ltd.
Phase 2/3B
Pyrotinib
Sinocelltech Ltd.
Phase 2/3B

Same molecule, other indications

Sctb41 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
CC
Indicative ·
47 / 100
View asset →
Advanced Malignant Solid TumorsDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →